The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
about
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidenceDo BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?Aromatase inhibitors in post-menopausal endometriosis.Tracking progesterone receptor-mediated actions in breast cancerSafety of aromatase inhibitors in the adjuvant setting.Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.The adjuvant endocrine treatment revolution: focus on anastrozole.Aromatase inhibitors: a safety comparison.Progression of endocrine therapies for breast cancer: where are we headed?The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients.Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.Endometriosis after menopause.Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments.The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
P2860
Q30380010-4C9C9B70-8B51-4E9A-8CF1-F873352DDF9FQ33555537-ACD04C9B-2264-4BC6-AA49-634DC7624959Q34194386-1E54951E-001F-46F6-88D3-B4E5FDA1E3E0Q34388848-E85072D0-797A-4E9F-A8BD-68E623BDCC21Q36026543-876E6187-99C8-4B65-B5EF-76F8200F86BDQ36274927-9560F9FD-7FFA-4B7A-891D-585EBB7331A8Q36546281-DD5657AD-9D09-4E56-9A0F-3E17D8324371Q36762444-145F362B-4ED3-4297-A0D4-0AA736D149E3Q37004695-9249F3A4-D458-444A-B63D-E67C1AE8E297Q37177723-99A4EA8C-9139-4A3F-BA3E-3C21C30FA0EDQ37338231-FC9422C0-6E65-45B0-8E7A-194B88A9198EQ38581631-23447C79-638B-42EA-A3F6-767BF2C90439Q38786052-FB586FC5-811B-474B-8DF3-3318AED1C1CEQ42940583-312E907E-97F5-41B6-88DC-3578F7A6B5B3
P2860
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The ATAC ('Arimidex', Tamoxife ...... ollowing 2 years of treatment.
@en
The ATAC ('Arimidex', Tamoxife ...... ollowing 2 years of treatment.
@nl
type
label
The ATAC ('Arimidex', Tamoxife ...... ollowing 2 years of treatment.
@en
The ATAC ('Arimidex', Tamoxife ...... ollowing 2 years of treatment.
@nl
prefLabel
The ATAC ('Arimidex', Tamoxife ...... ollowing 2 years of treatment.
@en
The ATAC ('Arimidex', Tamoxife ...... ollowing 2 years of treatment.
@nl
P2093
P356
P1433
P1476
The ATAC ('Arimidex', Tamoxife ...... ollowing 2 years of treatment.
@en
P2093
Jackson TL
Lansdown M
P304
P356
10.1093/HUMREP/DEI322
P407
P577
2005-10-06T00:00:00Z